Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
Agilent Technologies Analyst Ratings
What Analysts Are Saying About Vertex Pharmaceuticals Stock
AGCO Says Top Shareholder TAFE Cannot Use Massey Ferguson Tractor Brand
U.S. Companies With the Highest Percentage of Sales to China Have Outperformed WTD
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today
Bluebird Bio to Cut Workforce by About 25%
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
What's Going With Apellis Pharmaceuticals Stock Friday?
RBC Capital Reiterates Sector Perform on Vertex Pharmaceuticals, Maintains $431 Price Target
Vertex Pharmaceuticals Analyst Ratings
Agilent Technologies Declares $0.236 Dividend
Reported Earlier Intellia Therapeutics To Present Data From The Phase 2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2024 ACAAI Annual Scientific Meeting; To Host Investor Webcast On October 28, At 8:00 A.m. ET
Here's How Much $100 Invested In Agilent Technologies 20 Years Ago Would Be Worth Today
Bluebird Bio Analyst Ratings
Apellis Pharmaceuticals Analyst Ratings
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Intellia Therapeutics Analyst Ratings
Here's What the Harris-Trump Debate Means for US Stocks
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years